NewsBenzingaMacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial Benzinga 2026.10.23 13:24 (GMT+0) Open on Benzinga Other news How a DAO Vote Becomes a Treasury Transfer If Tesla Merges With SpaceX, How Many Bitcoin Would Elon's Companies Hold? Big Tech Earnings, Fed Decision and Other Key Things to Watch this Week AI delivers ‘zero financial payoff’ to most companies, Apollo economist says Wall Street Brunch: Fed And Hyperscaler Earnings (undefined:MSFT) EVV: Deep Discount Opens Up Creating Opportunity (NYSE:EVV)
